Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221129022> ?p ?o ?g. }
- W4221129022 endingPage "67" @default.
- W4221129022 startingPage "44" @default.
- W4221129022 abstract "Abstract DNA molecules are subject to various lesions that can be detrimental to the cells. DNA damage response (DDR) pathways encompass a variety of mechanisms that cells employ in response to DNA damage. While DDR promotes genomic stability in normal cells, it also protects cancer cells from DNA lesions, particularly against exogenous DNA‐damaging agents. Therefore, DDR pathways can be exploited to account for resistance to chemotherapy and radiotherapy and have the potential to be targeted in cancer treatment. Apart from the poly (ADP‐ribose) polymerase (PARP) inhibitors used in BRCA‐mutant cancers, other DDR inhibitors are being developed and tested in clinical trials. Based on the synthetic lethality theory, combination therapies utilizing DDR inhibitors have been explored and are currently undergoing clinical trials, with promising results in cancer treatment. Combination therapies typically employ a DDR inhibitor to sensitize cancer cells to traditional chemotherapeutic agents, radiotherapy, immunotherapy, and even PARP inhibitors. Herein, we focus on recent advances in DDR inhibitor‐based combination therapies other than PARP inhibitors, explore the advantages and disadvantages of the strategies, and discuss the current challenges and future perspectives." @default.
- W4221129022 created "2022-04-03" @default.
- W4221129022 creator A5001613477 @default.
- W4221129022 creator A5016160179 @default.
- W4221129022 creator A5020830182 @default.
- W4221129022 creator A5027339938 @default.
- W4221129022 creator A5032315855 @default.
- W4221129022 creator A5033136064 @default.
- W4221129022 creator A5035878842 @default.
- W4221129022 creator A5052114926 @default.
- W4221129022 creator A5059642129 @default.
- W4221129022 creator A5062444363 @default.
- W4221129022 creator A5081006428 @default.
- W4221129022 creator A5088672902 @default.
- W4221129022 date "2022-03-01" @default.
- W4221129022 modified "2023-09-26" @default.
- W4221129022 title "DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions" @default.
- W4221129022 cites W1473224886 @default.
- W4221129022 cites W1515564094 @default.
- W4221129022 cites W1553367038 @default.
- W4221129022 cites W1841331176 @default.
- W4221129022 cites W1912177776 @default.
- W4221129022 cites W1969885393 @default.
- W4221129022 cites W1973268287 @default.
- W4221129022 cites W1974010399 @default.
- W4221129022 cites W1984743945 @default.
- W4221129022 cites W1986830781 @default.
- W4221129022 cites W1987024877 @default.
- W4221129022 cites W1987610133 @default.
- W4221129022 cites W1994993231 @default.
- W4221129022 cites W1996318954 @default.
- W4221129022 cites W2001902450 @default.
- W4221129022 cites W2009007206 @default.
- W4221129022 cites W2016844537 @default.
- W4221129022 cites W2020165821 @default.
- W4221129022 cites W2027630134 @default.
- W4221129022 cites W2033008935 @default.
- W4221129022 cites W2037867164 @default.
- W4221129022 cites W2040860750 @default.
- W4221129022 cites W2045526190 @default.
- W4221129022 cites W2050086663 @default.
- W4221129022 cites W2056407774 @default.
- W4221129022 cites W2066411725 @default.
- W4221129022 cites W2071457560 @default.
- W4221129022 cites W2073467950 @default.
- W4221129022 cites W2074218748 @default.
- W4221129022 cites W2077436902 @default.
- W4221129022 cites W2083158919 @default.
- W4221129022 cites W2105663975 @default.
- W4221129022 cites W2113986107 @default.
- W4221129022 cites W2117389132 @default.
- W4221129022 cites W2129637612 @default.
- W4221129022 cites W2131592745 @default.
- W4221129022 cites W2132029465 @default.
- W4221129022 cites W2134647795 @default.
- W4221129022 cites W2135409663 @default.
- W4221129022 cites W2142031018 @default.
- W4221129022 cites W2145200068 @default.
- W4221129022 cites W2150055220 @default.
- W4221129022 cites W2159168998 @default.
- W4221129022 cites W2162730779 @default.
- W4221129022 cites W2171297405 @default.
- W4221129022 cites W2173456459 @default.
- W4221129022 cites W2212776653 @default.
- W4221129022 cites W2328481187 @default.
- W4221129022 cites W2343685960 @default.
- W4221129022 cites W2470708296 @default.
- W4221129022 cites W2476568892 @default.
- W4221129022 cites W2494174731 @default.
- W4221129022 cites W2507880355 @default.
- W4221129022 cites W2531549933 @default.
- W4221129022 cites W2547988452 @default.
- W4221129022 cites W2548423821 @default.
- W4221129022 cites W2553815939 @default.
- W4221129022 cites W2561396377 @default.
- W4221129022 cites W2562712448 @default.
- W4221129022 cites W2564559465 @default.
- W4221129022 cites W2587905891 @default.
- W4221129022 cites W2594301310 @default.
- W4221129022 cites W2597062310 @default.
- W4221129022 cites W2606996398 @default.
- W4221129022 cites W2612428976 @default.
- W4221129022 cites W2614952490 @default.
- W4221129022 cites W2627067328 @default.
- W4221129022 cites W2733154631 @default.
- W4221129022 cites W2741613334 @default.
- W4221129022 cites W2742885817 @default.
- W4221129022 cites W2745330422 @default.
- W4221129022 cites W2748694114 @default.
- W4221129022 cites W2753941672 @default.
- W4221129022 cites W2756992092 @default.
- W4221129022 cites W2766300480 @default.
- W4221129022 cites W2769583779 @default.
- W4221129022 cites W2775990711 @default.
- W4221129022 cites W2783113646 @default.
- W4221129022 cites W2783907570 @default.
- W4221129022 cites W2791913001 @default.
- W4221129022 cites W2795227812 @default.